Plasmodium falciparum malaria accounts for over half million deaths annually, with children being the most affected [
1]. Children are the most vulnerable because malaria immunity is dependent on age and exposure [
2,
3]. The blood stage of
P. falciparum is responsible for most of the malaria-associated pathology. Disease symptoms range from fever to more severe complications, including respiratory distress, metabolic acidosis, renal failure, pulmonary edema and cerebral malaria. The clinical spectrum of symptomatic disease is caused by the asexual blood stages of
Plasmodium, where the parasite undergoes cyclic replication within human erythrocytes [
4]. Although the pathogenesis of malaria is not completely understood, it is believed to arise from the concerted effects of host and parasite factors, including the sequestration of infected erythrocytes in microvasculature, local and systemic inflammation [
5]. Naturally acquired immunity is known to require antibody responses. The protective role of antibodies in combating malaria was first established by passive transfer of immunoglobulin G (IgG) from clinically immune adults into children with severe malaria, which rapidly attenuated the severity and burden of disease [
6]. This has been supported by immuno-epidemiological studies, where antibodies to parasite antigens have been found to be associated with protection from clinical episodes in endemic areas [
7‐
14]. Antibodies may limit the growth of blood-stage parasites and the development of clinical symptoms by several known mechanisms. These include blocking erythrocyte invasion [
15‐
17], opsonising parasitized erythrocytes for phagocytic clearance [
18,
19], monocyte-mediated antibody-dependent cellular killing [
20,
21], and complement-mediated lysis [
22], and in addition meddling with the adherence of infected erythrocytes to vascular endothelium [
4]. Inadequate production of antibodies to
Plasmodium antigens and their subsequent loss in the absence of persistent exposure has been proposed to impair B-cell immunological memory advancement [
4]. Memory B-cells (MBCs) play an important role in durable resistance to different pathogens by boosting the immune response in times of secondary exposure. Studies have shown that antibody production can be sustained through re-stimulation of MBCs by persistent antigens [
23] or by non-proliferating long lived plasma cells [
24,
25]. Protection of the adult and the newborn is ensured by antibodies mostly of IgG and IgA isotypes. MBCs induced by natural infection or vaccination correspond to switched MBCs. In the peripheral blood, another population of MBCs, called IgM memory [
26‐
28] has been described with different origin, function and significance. IgM MBCs, also known as natural memory or natural effector memory cells [
29], develop in the absence of germinal centres [
30], generate extra-follicular thymus-independent responses and produce natural antibodies [
31]. Because of the host immature immune system and the antigenic variation of the malaria parasite, development of effective B-cells and antibody responses occurs after repeated years of exposure [
32‐
36]. It has also been speculated that
Plasmodium infection meddles with development and maintenance of B-cell memory response [
37‐
41]. There is still need to fully understand the development, regulation and maintenance of immunity against malaria [
36,
42,
43]. B-cell phenotypes created amid malaria bouts demonstrate the B-cells linked with malaria immunity development. Diverse research has portrayed numerous B-cell phenotypes in individuals exposed to different malaria episodes [
35,
37,
38,
44‐
49]. Nahrendorf et al. [
50] showed gradual acquisition of MBCs and antibodies recognizing pre-erythrocytic and cross-stage antigens after
P. falciparum sporozoite immunization. However, the magnitude of these humoral responses did not correlate with protection but directly reflected parasite exposure in chemoprophylaxis and sporozoite immunization. In African youngsters after experiencing intense malaria, an expansion in both the total memory and transitional B-cell populaces was observed [
51]. It is important to note that this earlier research studied the whole B-cell populace and did not estimate
Plasmodium falciparum (Pf+) specific B cells. Elispot assay has been used to try and find parasite specific cells, for example to show that even if antigen-specific antibodies were not detected in plasma, antigen-specific B-cells could still be found circulating in the blood, suggesting that these could be maintained independently of long-lived plasma cells [
52]. However, Elispot needs activation and survival of cells for a relatively long time, and compared to ELISA-based assays, flow cytometry is a good method for estimation of antigen-specific cells. While dealing with intricate antigens, flow cytometry has been shown to be a better assay option [
53]. Malaria calls for flow cytometry analysis since it has a scope of parasite antigens that individually have a low number of specific B-cells. ELISA-based measures when improved can only quantify 70% of the response determined by flow cytometry [
53]. Flow cytometry is advantageous in that there is no need of cell incitement thereby expanding the odds of incorporating all cells in the reading. In order to acknowledge how Pf+ B-cells are actuated and kept up in vivo, these cells should be isolated from other B-cells. Here, the flow cytometry technique for detection of Pf+ B-cells which was developed by Lugaajju et al. [
54] was applied to monitor the development of Pf+ B-cell sub-populations in newborns from time of birth until 9 months and in their respective mothers, in a malaria endemic area.